RI
RTW Investments Portfolio holdings
AUM
$7.02B
This Quarter Return
-17.95%
1 Year Return
+28.16%
3 Year Return
+245.48%
5 Year Return
+425.65%
10 Year Return
+5,642.23%
AUM
$319M
AUM Growth
+$319M
(-5.4%)
Cap. Flow
+$54.6M
Cap. Flow
% of AUM
17.13%
Top 10 Holdings %
Top 10 Hldgs %
71.74%
Holding
47
New
13
Increased
16
Reduced
7
Closed
5
Top Buys
| 1 |
LJPC
La Jolla Pharmaceutical Company
LJPC
|
$22.1M |
| 2 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$16.6M |
| 3 |
Incyte
INCY
|
$11.9M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
$9.86M |
| 5 |
Atara Biotherapeutics
ATRA
|
$8.27M |
Top Sells
| 1 |
Gyre Therapeutics
GYRE
|
$10.7M |
| 2 |
DYAX
DYAX CORPORATION
DYAX
|
$8.47M |
| 3 |
iShares 20+ Year Treasury Bond ETF
TLT
|
$3.88M |
| 4 |
United States Oil Fund
USO
|
$3.28M |
| 5 |
Arrowhead Research
ARWR
|
$2.67M |
Sector Composition
| 1 | Healthcare | 84.83% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Alnylam Pharmaceuticals
ALNY
$58.5B
| $42.9M | 13.32% | 533,660 +122,644 | +30% | +$9.86M |
|
|
2
Incyte
INCY
$16.5B
| $33.5M | 10.39% | 303,212 +108,212 | +55% | +$11.9M |
|
|
LJPC
3
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $30M | 9.33% | 1,080,331 +796,631 | +281% | +$22.1M |
|
4
BioCryst Pharmaceuticals
BCRX
$1.74B
| $25.4M | 7.89% | 2,228,206 -33,155 | -1% | -$378K |
|
|
KITE
5
DELISTED
Kite Pharma, Inc.
KITE
| $20.9M | 6.5% | 375,476 -24,524 | -6% | -$1.37M |
|
|
ACHN
6
DELISTED
Achillion Pharmaceuticals, Inc.
ACHN
| $17.9M | 5.56% | 2,589,818 +74,385 | +3% | +$514K |
|
|
MRTX
7
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $16.6M | 5.16% | +482,069 | New | +$16.6M |
|
|
DRNA
8
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $16.5M | 5.12% | 2,005,238 +725,352 | +57% | +$5.96M |
|
|
BLUE
9
DELISTED
bluebird bio
BLUE
| $13M | 4.03% | 151,594 +46,594 | +44% | +$3.99M |
|
|
10
Arrowhead Research
ARWR
$3.05B
| $12.1M | 3.75% | 2,097,185 -462,815 | -18% | -$2.67M |
|
|
FPRX
11
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $11M | 3.41% | 713,954 +153,517 | +27% | +$2.36M |
|
|
AGEN
12
Agenus
AGEN
$133M
| $9.59M | 2.98% | 2,084,142 +31,227 | +2% | +$144K |
|
|
13
Atara Biotherapeutics
ATRA
$84.6M
| $8.27M | 2.57% | +262,995 | New | +$8.27M |
|
14
Celldex Therapeutics
CLDX
$1.47B
| $7.58M | 2.35% | 718,729 +247,175 | +52% | +$2.61M |
|
|
SSRG
15
DELISTED
SYMMETRY SURGICAL INC COMMON STK
SSRG
| $7.19M | 2.23% | 807,442 +106,591 | +15% | +$949K |
|
16
Bristol-Myers Squibb
BMY
$96B
| $6.06M | 1.88% | 102,425 +4,971 | +5% | +$294K |
|
|
CORI
17
DELISTED
Corium International, Inc.
CORI
| $5.38M | 1.67% | 575,212 +220,205 | +62% | +$2.06M |
|
18
Omeros
OMER
$283M
| $5.37M | 1.67% | +490,000 | New | +$5.37M |
|
19
Regenxbio
RGNX
$451M
| $4.51M | 1.4% | +204,494 | New | +$4.51M |
|
|
GBT
20
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $3.9M | 1.21% | +92,399 | New | +$3.9M |
|
21
Lipocine
LPCN
$15.8M
| $2.51M | 0.78% | 212,497 +3,164 | +2% | +$37.4K |
|
|
IVTY
22
DELISTED
Invuity, Inc
IVTY
| $2.45M | 0.76% | 175,000 +10,000 | +6% | +$140K |
|
|
DYAX
23
DELISTED
DYAX CORPORATION
DYAX
| $2.2M | 0.68% | 115,358 -443,783 | -79% | -$8.47M |
|
|
LENS
24
DELISTED
Presbia PLC Ordinary Shares
LENS
| $1.92M | 0.6% | 350,000 | – | – |
|
|
25
Gyre Therapeutics
GYRE
$703M
| $1.78M | 0.55% | 380,806 -2,284,837 | -86% | -$10.7M |
|